Delivery Order SPE2DB20D3103-SPE2DB24FM6M3
- Not listed
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a Delivery Order valued at $1,013.00 for the procurement of PROCTOFOAM-HC 1%-1% FOAM 10GM medical supplies. The award was made by the Defense Logistics Agency (DLA), a defense agency within the U.S. Department of Defense, and has an ultimate completion date of October 18, 2023. The contract is a Firm Fixed Price agreement and is not designated with a set-aside. Amerisourcebergen, a major...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $1,153.81 under a larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical. The contract is for the supply of medical products, including the PROCTOFOAM-HC 1%-1% FOAM 10GM pharmaceutical item. The IDC with the DLA is valued at up to $999,999,999.00 and runs through November 2026, serving as a primary vehicle for...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract, valued at $3,801.92, is for the delivery of PROCTOFOAM-HC 1%-1% FOAM 10GM medical supplies. This is a Firm Fixed Price delivery order contract without any set-aside designations, indicating open competition. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
- This federal contract award was made by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $2,908.39 firm fixed-price delivery order is for the supply of PROCTOFOAM-HC 1%-1% FOAM 10GM medical products. This award is part of a larger Indefinite Delivery Contract (IDC) between the DLA and Cencora, Inc. valued at up to $999,999,999.00, which serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of...
- This federal contract award, valued at $2,483.31, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical...
- This federal contract award, valued at $13,178.93, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract is a delivery order (SPE2DB24FSMQ9) for the procurement of PROCTOFOAM-HC 1%-1% FOAM 10GM medical supplies, with a completion date of March 13, 2024. Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, has an Indefinite Delivery Contract (IDC) with the DLA...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) Troop Support Medical for the delivery of PROCTOFOAM-HC 1%-1% FOAM 10GM. The $6,084.66 firm fixed-price contract has an ultimate completion date of November 5, 2024. This award is a delivery order under an existing Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical, which serves as a...
- This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $5,210.14, is for the delivery of PROCTOFOAM-HC 1%-1% FOAM 10GM medical supplies. It is a firm fixed-price delivery order contract without any set-aside designation, indicating open competition. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC)...
- This federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp. is a Delivery Order with a Firm Fixed Price valued at $1,761.96. The contract is for the procurement of PROCTOFOAM-HC 1%-1% FOAM 10GM, a medical supply item, with a completion date of January 10, 2025. Amerisourcebergen, a major pharmaceutical distributor, holds a significant Indefinite Delivery Contract (IDC) valued at $999,999,999 with the DLA Troop Support Medical that runs through November...
- This federal contract award, with a ceiling value of $1,162.23, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, which does not have a set-aside designation, is a delivery order for the procurement of PROCTOFOAM-HC 1%-1% FOAM 10GM medical supplies. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB24FM6M3Delivery Order
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a Delivery Order (Contract # SPE2DB20D3103) with a Ceiling Value of $1,182.75. The award was made by the Defense Logistics Agency (DLA) Troop Support Medical, a defense agency, for the procurement of PROCTOFOAM-HC 1%-1% FOAM 10GM medical supplies. The contract has a Firm Fixed Price pricing type and a completion date of February 13, 2024. It is not designated as a set-aside contract. Amerisourcebergen, a major pharmaceutical distributor, holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026, which serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. Additionally, Amerisourcebergen maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 2/12/24 |